Evaluation of ERK as a therapeutic target in acute myelogenous leukemia

Leukemia. 2020 Feb;34(2):625-629. doi: 10.1038/s41375-019-0552-3. Epub 2019 Aug 27.

Ellen Weisberg^#^{1

2}, Chengcheng Meng^#³, Abigail Case^#³, Martin Sattler^{3

4}, Hong L Tiv⁵, Prafulla C Gokhale⁵, Sara Buhrlage⁶, Jinhua Wang⁷, Nathanael Gray⁷, Richard Stone^{3

4}, Suiyang Liu³, Shripad V Bhagwat⁸, Ramon V Tiu⁸, Sophia Adamia^{3

4}, James D Griffin^{9

10}

¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.
² Department of Medicine, Harvard Medical School, Boston, MA, USA. ellen_weisberg@dfci.harvard.edu.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁴ Department of Medicine, Harvard Medical School, Boston, MA, USA.
⁵ Experimental Therapeutic Core, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215.
⁶ Department of Cancer Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA, 02215.
⁷ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
⁸ Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. james_griffin@dfci.harvard.edu.
¹⁰ Department of Medicine, Harvard Medical School, Boston, MA, USA. james_griffin@dfci.harvard.edu.

^# Contributed equally.

No abstract available

Publication types